Akebia Therapeutics Advances Vafseo Prescribing Access and Rare Kidney Disease Pipeline

Akebia Therapeutics has expanded Vafseo's prescribing access to 275,000 dialysis patients, completed patient enrollment in the VOICE study, and presented Phase 3 INNO2VATE trial findings. The company is advancing its mid-stage pipeline with the VOCAL study, enrolling around 350 participants for rare kidney disease treatments. Akebia has a market capitalization of $403.36 million and is listed on the NASDAQ exchange.